Studying Quality of Life During Neuroendocrine Tumor Treatment

614 Background: Diarrhea is a common quality of life limiting symptom seen in neuroendocrine tumor patient. Diarrhea in these patients could be due to excessive serotonin production, secondary to post-operative short gut syndrome, steatorrhea from somatostatin analogs, bile acid colitis or intestinal bacterial overgrowth. In this study we summarize our single center experience with enterade. Methods: Medical records of all the NET patients treated with enterade for symptomatic diarrhea were retrospectively reviewed after appropriate IRB approval. Patients were treated at Markey cancer center between May 2017-June 2019. Results: Total 98 patients were offered enterade. enterade was instructed to be taken as one 8 Oz bottle BID for 1 week. Antidiarrheal efficacy data was available on 49 patients at the time of abstract submission. 37 (75%) patients had GEPNETs, 8 had bronchial NETs, 1 gynecological NET and 3 patients had unknown primary. 28 (57%) patients had history of prior bowel resection either for primary neuroendocrine tumor resection or debulking. 28 (57%) patients were on somatostatin analog at the time of initiation of enterade. 42 (85%) out of 49 patients reported subjective improvement in diarrheal symptoms. 27 (64%) out of these 42 responders reported at least 50 percent reduction in diarrhea frequency. Conclusions: 85% (42/49) neuroendocrine tumor patients reported improvement in diarrhea with enterade. 64% (27/42) reported more than 50% reduction in diarrhea frequency. A prospective Phase II study of enterade in neuroendocrine tumor patients with quality of life limiting diarrhea is currently being conducted (NCT03722511).

Download Full-text

Regular Dental Visits: Influence on Health-Related Quality of Life in 1,607 Patients with Oral Squamous Cell Carcinoma

International Journal of Dentistry ◽

10.1155/2017/9638345 ◽

2017 ◽

Vol 2017 ◽

pp. 1-6 ◽

Cited By ~ 2

Author(s):

Simon Spalthoff ◽

Henrik Holtmann ◽

Gertrud Krüskemper ◽

Rüdiger Zimmerer ◽

Jörg Handschel ◽

...

Keyword(s):

Quality Of Life ◽

Squamous Cell Carcinoma ◽

Oral Cancer ◽

Health Related Quality ◽

Tumor Treatment ◽

Related Quality ◽

Health Related ◽

Group A ◽

Group B

Background. The incidence of oral squamous cell carcinoma (OSCC) is in the top 10 of all cancer entities. Regular oral examinations by dentists play an important role in oral cancer prevention.Methods. Patients with OSCC (n=1,607) and physicians (n=1,489) completed questionnaires during the DÖSAK Rehab Study. The psychosocial and functional factors collected in these questionnaires were assessed in the present study. We compared patients who visited their dentist at least once a year (group A) with those who visited their dentist less than once a year (group B).Results. Patients in group A had significantly better health-related quality of life after tumor treatment than patients in group B. Patients in group A also had a smaller tumor size and less lymph node metastasis and lost fewer teeth during the treatment. This resulted in better prosthetic rehabilitation and better psychological status after tumor treatment.Conclusions. Dentists play an important role in the early recognition of oral cancer. This study should encourage dentists to take a more active role in oral cancer prevention.

Download Full-text

Quality of life of head and neck cancer patients after tumor treatment and subsequent maxillofacial rehabilitation

10.14232/phd.1349 ◽

2012 ◽

Author(s):

Judit Nagy

Keyword(s):

Quality Of Life ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Tumor Treatment

Download Full-text

Health-related quality of life and emotional problems in children surviving brain tumor treatment: A descriptive study of 2 cohorts

Pediatric Hematology and Oncology ◽

10.1080/08880018.2016.1191101 ◽

2016 ◽

Vol 33 (5) ◽

pp. 282-294 ◽

Cited By ~ 1

Author(s):

Arianne B. Dessens ◽

Michael C. van Herwerden ◽

Femke K. Aarsen ◽

Erwin Birnie ◽

Coriene E. Catsman-Berrevoets

Keyword(s):

Quality Of Life ◽

Brain Tumor ◽

Emotional Problems ◽

Descriptive Study ◽

Health Related Quality ◽

Tumor Treatment ◽

Related Quality ◽

Health Related

Download Full-text

Health-Related Quality of Life of Patients With Neuroendocrine Tumor Compared to the United States General Population

Pancreas ◽

10.1097/01.mpa.0000363909.53692.01 ◽

2010 ◽

Vol 39 (2) ◽

pp. 271 ◽

Cited By ~ 2

Author(s):

Jennifer L. Beaumont ◽

Zhimei Liu ◽

Seung Choi ◽

James C. Yao ◽

David Cella

Keyword(s):

Quality Of Life ◽

United States ◽

General Population ◽

Neuroendocrine Tumor ◽

The United States ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Download Full-text

The Emesis Trial: Depressive Patients with Brain Tumors are more Affected by Chemotherapy-induced Nausea and Vomiting

10.21203/rs.3.rs-327602/v1 ◽

2021 ◽

Author(s):

Vera Dufner ◽

Almuth Friederike Keßler ◽

Larissa Just ◽

Peter Hau ◽

Elisabeth Bumes ◽

...

Keyword(s):

Quality Of Life ◽

Brain Tumors ◽

Nausea And Vomiting ◽

Tumor Treatment ◽

Delayed Nausea ◽

Before And After ◽

Long Acting ◽

Eortc Qlq ◽

Loss Of Appetite

Abstract Purpose: Patients with malignant brain tumors face a limited life expectancy and at the same time, they suffer from afflicting symptoms and undesired effects of tumor treatment. Apart from bone marrow suppression, standard chemotherapy with temozolomide causes nausea, emesis and loss of appetite. In this pilot study, we investigated how chemotherapy-induced nausea and vomiting (CINV) affects the patients’ levels of depression and their quality of life. Methods: In this prospective observational multicentre study (n = 87), nausea, emesis and loss of appetite were evaluated with an expanded MASCC questionnaire, covering ten days during the first and the second cycle of chemotherapy. Quality of life was assessed with the EORTC QLQ-C30 and BN 20 questionnaire and levels of depression with the PHQ-9 inventory before and after the first and second cycle of chemotherapy. Results: CINV affected a minor part of patients. If present, it reached its maximum at day 3 and decreased to baseline level not before day 8. Levels of depression increased significantly after the first cycle of chemotherapy, but decreased during the further course of treatment. Patients with higher levels of depression were more severely affected by CINV and showed a lower quality of life through all time-points. Conclusion: We conclude that symptoms of depression should be perceived in advance and treated in order to avoid more severe side effects of tumor treatment. Additionally, in affected patients, delayed nausea was most prominent, pointing towards an activation of the NK1 receptor. We conclude that long acting antiemetics are necessary to treat temozolomide-induced nausea.

Download Full-text

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Case Reports in Oncology ◽

10.1159/000441775 ◽

2015 ◽

Vol 8 (3) ◽

pp. 461-465 ◽

Cited By ~ 10

Author(s):

Corey A. Carter ◽

Aiste Degesys ◽

Bryan Oronsky ◽

Jan Scicinski ◽

Scott Z. Caroen ◽

...

Keyword(s):

Quality Of Life ◽

Beneficial Effect ◽

Neuroendocrine Tumor ◽

Carcinoid Syndrome ◽

Anticancer Agent ◽

Phase Ii Trial ◽

Secretory Granules ◽

Vasoactive Peptides ◽

Treatment Refractory

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms defined by the presence of cells with secretory granules and the potential to produce and release high levels of vasoactive peptides into the circulation, leading to severe flushing and diarrhea, which may adversely affect quality of life. This report presents the case of a 64-year-old man with chronic refractory diarrhea due to pulmonary NET treated with the experimental anticancer agent RRx-001 in a phase II trial called TRIPLE THREAT with subsequent resolution of his diarrhea.

Download Full-text